Cambridge Investment Research Advisors Inc. Makes New $312,000 Investment in Dynavax Technologies Corporation (NASDAQ:DVAX)

Cambridge Investment Research Advisors Inc. purchased a new position in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 24,044 shares of the biopharmaceutical company’s stock, valued at approximately $312,000.

Several other hedge funds have also recently added to or reduced their stakes in DVAX. Deep Track Capital LP raised its holdings in Dynavax Technologies by 42.0% during the 4th quarter. Deep Track Capital LP now owns 17,791,486 shares of the biopharmaceutical company’s stock worth $227,197,000 after purchasing an additional 5,265,000 shares during the last quarter. Deerfield Management Company L.P. Series C grew its position in shares of Dynavax Technologies by 23,990.1% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 5,193,823 shares of the biopharmaceutical company’s stock worth $66,325,000 after buying an additional 5,172,263 shares during the period. Norges Bank acquired a new stake in shares of Dynavax Technologies during the 4th quarter worth approximately $7,762,000. D. E. Shaw & Co. Inc. grew its position in shares of Dynavax Technologies by 34.0% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,918,340 shares of the biopharmaceutical company’s stock worth $24,497,000 after buying an additional 486,981 shares during the period. Finally, WINTON GROUP Ltd grew its position in shares of Dynavax Technologies by 339.0% during the 4th quarter. WINTON GROUP Ltd now owns 426,814 shares of the biopharmaceutical company’s stock worth $5,450,000 after buying an additional 329,579 shares during the period. Institutional investors own 96.96% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on DVAX shares. JMP Securities reduced their price objective on shares of Dynavax Technologies from $33.00 to $31.00 and set a “market outperform” rating for the company in a research report on Wednesday, May 7th. The Goldman Sachs Group reduced their price objective on shares of Dynavax Technologies from $12.00 to $10.00 and set a “sell” rating for the company in a research report on Thursday, April 17th. Finally, Wall Street Zen downgraded shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $24.00.

Dynavax Technologies Stock Performance

Shares of DVAX stock opened at $10.58 on Friday. The firm has a market capitalization of $1.27 billion, a PE ratio of -20.35 and a beta of 1.03. The firm has a fifty day simple moving average of $10.06 and a two-hundred day simple moving average of $11.79. The company has a current ratio of 11.93, a quick ratio of 10.84 and a debt-to-equity ratio of 0.49. Dynavax Technologies Corporation has a 12 month low of $9.22 and a 12 month high of $14.63.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.14). The business had revenue of $68.16 million for the quarter, compared to the consensus estimate of $70.01 million. Dynavax Technologies had a negative net margin of 20.39% and a positive return on equity of 3.59%. Analysts forecast that Dynavax Technologies Corporation will post 0.32 EPS for the current fiscal year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.